Combination Chemotherapy for Recurrent Ovarian Cancer
Name of the Trial
Phase III Randomized Study of Carboplatin With or Without Pegylated Doxorubicin HCl Liposome in Patients with Platinum-Sensitive Recurrent Ovarian Epithelial or Primary Peritoneal Cancer (SWOG-S0200). See the protocol summary.
Dr. David Samuel Alberts of the Arizona Cancer Center and the Southwest Oncology Group.
Why This Trial Is Important
Ovarian epithelial cancer is the leading cause of death from gynecologic malignancies in the United States. Surgery followed by chemotherapy with a platinum-based agent (such as carboplatin) is the standard treatment for advanced stage ovarian epithelial cancer.
Ovarian cancer that remains progression-free for a period of more than six months after chemotherapy has been completed is called platinum sensitive, meaning the therapy has produced a lasting clinical response. Patients who experience a recurrence of platinum-sensitive disease will likely benefit from another round of platinum therapy, which may be given in combination with a non-platinum agent.
Primary peritoneal cancer is a rare cancer that grows in the peritoneum, a membrane that lines the walls of the abdomen. It is biologically similar to ovarian epithelial cancer.
This trial will study the effectiveness of carboplatin with or without pegylated liposomal doxorubicin (Doxil®) in treating patients who have recurrent ovarian epithelial or primary peritoneal cancer.
"Whether two-drug combinations are superior to single agent carboplatin in platinum-sensitive disease remains a critical, unanswered question in the management of women experiencing recurrent advanced disease," said Dr. Alberts. "Furthermore, this study should confirm the efficacy of pegylated liposomal doxorubicin in platinum-sensitive, recurrent, advanced ovarian cancer."
This trial is no longer accepting new patients. To locate other ovarian cancer clinical trials, search the NCI's database of clinical trials or call the NCI's Cancer Information Service at 1-800-4-CANCER (1-800-422-6237). The call is toll free and completely confidential.